A Potential Drug Target or Biomarker: Uncharacterized Protein C12orf63 (Chromosome 12 Open Reading Frame 63)

Target Name: Putative uncharacterized protein C12orf63

NCBI ID: P27942

Putative uncharacterized protein C12orf63

Other Name(s): Chromosome 12 open reading frame 63

A Potential Drug Target or Biomarker: Uncharacterized Protein C12orf63 (Chromosome 12 Open Reading Frame 63)

Cancer is one of the leading causes of human morbidity and mortality, and the development of new therapeutic approaches to combat this disease is crucial. One promising approach is the identification of potential drug targets or biomarkers for cancer. In this article, we focus on the uncharacterized protein C12orf63 (Chromosome 12 Open Reading Frame 63), which may serve as a drug target or biomarker for various types of cancer.

Overview of C12orf63

C12orf63 is a protein located on Chromosome 12 (12q34) open reading frame 63. It is a non-coding RNA molecule that contains 63 amino acid residues. The protein is expressed in various tissues and has been implicated in various cellular processes, including cell adhesion, migration, and invasion.

Previous studies have identified several potential binding sites on C12orf63 for small molecules, peptides, and other biomolecules. However, the full potential of C12orf63 as a drug target or biomarker remains unexplored.

Potential Druggability of C12orf63

C12orf63 is a potential drug target due to its unique structure and various cellular processes. Its unique amino acid sequence, composed of alanine, aspartic acid, glutamic acid, and glycine residues, may allow it to interact with small molecules and other biomolecules with specificity.

The protein's amino acid sequence also suggests potential binding sites for small molecules that can modulate its activity. For instance, C12orf63 has been shown to interact with the small molecule drugletisin, which is a potent inhibitor of tyrosine kinase. This interaction may play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

C12orf63 may also serve as a biomarker for cancer, as its expression has been observed in various types of cancer. For instance, C12orf63 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. This finding may indicate that C12orf63 could be a useful biomarker for cancer diagnosis and monitoring.

Conclusion

C12orf63 is an uncharacterized protein that has potential as a drug target or biomarker for various types of cancer. Its unique amino acid sequence and potential binding sites make it an attractive target for small molecules and other biomolecules. Further studies are needed to fully explore its potential as a drug target or biomarker.

Protein Name: Putative Uncharacterized Protein C12orf63

The "Putative uncharacterized protein C12orf63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Putative uncharacterized protein C12orf63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets